Table 1

Baseline characteristics and large B-cell lymphoma risk factors of the 27 patients with rheumatic diseases

Case noRheumatic diseasesSexAge (years) at LBCL diagnosisYears from rheumatic disease symptoms to LBCL diagnosisIPIBulk diseasec-MYC rearrangementsLBCL
1pSSF5232Low/intermediate+DLBCL, NOS
2pSSF5919Intermediate/highNADLBCL, NOS
3pSSF5318Low/intermediateDLBCL, NOS
4pSSF4838LowNADLBCL, NOS
5pSSF8322Intermediate/highNADLBCL, NOS
6pSSF5913LowNADLBCL
7pSSF4726HighDLBCL
8pSSF5122HighNADLBCL, NOS
9pSSF396HighDLBCL, NOS
10pSSF6215HighNANADLBCL, NOS
11pSSF4522Intermediate/high+NADLBCL
12pSSF7018HighNADLBCL
13pSSF7318High+DLBCL
14pSSF7324Intermediate/highDLBCL, NOS
15pSSF6715High+DLBCL, NOS
16pSSF303LowDLBCL, NOS
17pSSF6120Intermediate/highEBV-positive DLBCL, NOS; monomorphic
18pSSF4221Low/intermediateNAEBV-positive DLBCL, NOS; polymorphic
19pSSF4322LowNANATHRLBCL
20pSSF5714Intermediate/highNATHRLBCL
21SLE and sSSF6125Low/intermediate+DLBCL, NOS
22SLE and APSF582Low+DLBCL, NOS
23SLEM605Intermediate/highDLBCL, NOS
24RAF5722Intermediate/highDLBCL, NOS
25RA and sSSF6219HighDLBCL, NOS
26SSc and sSSF5926LowDLBCL, NOS
27SSc and sSSF590Low/intermediateNADLBCL
  • +, positive; −, negative; APS, antiphospholipid syndrome; DLBCL, NOS, diffuse large B-cell lymphoma, not otherwise specified; EBV, Epstein-Barr virus; F, female; IPI, International Prognostic Index; LBCL, large B-cell lymphoma; M, male; NA, not available; pSS, primary Sjogren’s syndrome; RA, rheumatoid arthritis; SSc, systemic sclerosis; sSS, secondary Sjogren’s syndrome; THRLBCL, T-cell/histiocyte-rich large B-cell lymphoma.